Ltd. Kck Sells 5,270,845 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NeuroPace Stock Performance

NPCE opened at $13.77 on Friday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The company’s fifty day moving average price is $12.49 and its two-hundred day moving average price is $9.44. NeuroPace, Inc. has a 1-year low of $5.45 and a 1-year high of $17.45. The company has a market cap of $411.03 million, a price-to-earnings ratio of -13.77 and a beta of 2.05.

Analyst Ratings Changes

Several brokerages recently issued reports on NPCE. JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company upped their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, January 30th. Finally, UBS Group started coverage on shares of NeuroPace in a report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, NeuroPace has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

Institutional Trading of NeuroPace

Several institutional investors and hedge funds have recently made changes to their positions in NPCE. BNP Paribas Financial Markets purchased a new stake in shares of NeuroPace in the fourth quarter valued at about $29,000. Wells Fargo & Company MN raised its holdings in shares of NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after purchasing an additional 2,279 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after purchasing an additional 6,181 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in shares of NeuroPace in the fourth quarter valued at about $103,000. Finally, Birchview Capital LP purchased a new stake in shares of NeuroPace in the fourth quarter valued at about $112,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.